Some biotech stories are born in the clouds of academia and die in the fog of regulatory indecision. But every now and then, a company drops with the weight of something real, science with teeth, a market with hunger, and leadership that knows exactly what to do with both. Syntis Bio isn’t just here to play. They’re here to digest the market.
Founded in 2022 out of MIT’s Langer and Traverso labs, Syntis Bio started with a very Gatesian mission, figure out how to deliver oral meds more effectively for kids in low-resource settings. That problem cracked open a much bigger door. Behind it? The untapped potential of the small intestine as a delivery engine for everything from metabolic resets to rare enzyme therapies. What started as a public health initiative turned into a platform that could change how we treat obesity, diabetes, and rare metabolic diseases, without needles, without surgery, and without wrecking lean mass in the process.
At the center of the action is Co-founder, President, and CEO Rahul K. Dhanda, fresh off co-founding Sherlock Biosciences and building the first FDA-authorized CRISPR product. He’s backed by biotech royalty, Robert Langer, Sc.D., the walking biotech ecosystem, and Giovanni Traverso, M.B., Ph.D., whose dual citizenship in MIT’s mechanical engineering department and Brigham and Women’s gastroenterology wing makes him the rare founder fluent in both molecules and machinery. Add Vasu Sethuraman, Ph.D. as Head of R&D, ex-Synlogic, Ironwood, Alkermes, and you’ve got a team that knows how to build, scale, and ship.
And now, they’ve locked in $38 million in new fuel, $33 million in Series A equity led by Cerberus Ventures, plus $5 million in NIH grants. Returning heavyweights like BOLD Capital, Safar Partners, and W.R. Berkley showed up again, joined by new believers from Mansueto Investments, Woori Venture Partners, and Apollo Labs. This wasn’t a “let’s see what happens” round. It was oversubscribed. People wanted in.
The money backs a pipeline that’s already sprinting. SYNT-101, their obesity candidate, mimics the metabolic rewiring of gastric bypass without the scalpel. Early data shows 1% weekly weight loss in rodents with full muscle retention. Meanwhile, SYNT-202 and SYNT-203, enzymatic therapies for homocystinuria and maple syrup urine disease, are IND-bound by 2025, with preclinical work in non-human primates already done. All of it powered by their SYNT™ platform, which lays down a transient polymer coating in the small intestine using mussel-inspired chemistry. Think of it like bioengineered surfboard wax, designed to stay put just long enough to reroute metabolism, then disappear without a trace.
So what’s the move? Obesity, a $48B juggernaut by 2030. Rare diseases, where there’s no competition because there’s no treatment. And a polymer platform that turns injection-only biologics into once-daily pills. That’s not a pipeline, it’s a category creator.
This is how you build biotech with bite. Congratulations to Rahul K. Dhanda, Robert Langer, Giovanni Traverso, Vasu Sethuraman, and the entire Syntis Bio team on a raise that’s going to move molecules, markets, and mindsets.
